Evidence map›Paper›PMID 26839262›Full record

ArticleMolecular cancer research : MCR2016

KLF4 Suppresses Tumor Formation in Genetic and Pharmacological Mouse Models of Colonic Tumorigenesis.

Amr M Ghaleb, Enas A Elkarim, Agnieszka B Bialkowska, Vincent W Yang

Open access · bronzeAbstract read
In one paragraph

Article in Molecular cancer research : MCR, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 33 citations in OpenAlex.

  1. Trial
  2. Cells · 2025
    Review
  3. Article
  4. International journal of molecular sciences · 2025
    Article
  5. Article
  6. Review
  7. Review
  8. The Roles of Zinc Finger Proteins in Colorectal Cancer.International journal of molecular sciences · 2023
    Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Amr M GhalebDepartment of Medicine, Stony Brook University, Stony Brook, New York.
Enas A ElkarimDepartment of Medicine, Stony Brook University, Stony Brook, New York.
Agnieszka B BialkowskaDepartment of Medicine, Stony Brook University, Stony Brook, New York.
Vincent W YangDepartment of Medicine, Stony Brook University, Stony Brook, New York. Department of Physiology and Biophysics, Stony Brook University, Stony Brook, New York. vincent.yang@stonybrookmedicine.edu.
Stony Brook University · US

Funding

REGULATION OF INTESTINAL EPITHELIAL CELL PROLIFERATIONR01DK052230 · NIDDK · STATE UNIVERSITY NEW YORK STONY BROOK · PI Vincent W Yang · 1997 to 2026
$8.7M
MECHANISMS OF INTESTINAL TUMORIGENESISR01CA084197 · NCI · STATE UNIVERSITY NEW YORK STONY BROOK · PI YANG, VINCENT W · 2000 to 2020
$7.5M
Targeted Approach for Prevention and Therapy of Colorectal CancerR01CA172113 · NCI · STATE UNIVERSITY NEW YORK STONY BROOK · PI YANG, VINCENT W · 2013 to 2017
$1.7M
Molecular Mechanisms Regulating Intestinal HomeostasisR01DK093680 · NIDDK · STATE UNIVERSITY NEW YORK STONY BROOK · PI YANG, VINCENT W · 2012 to 2016
$1.7M
NCI NIH HHS CA084197NCI NIH HHS R01 CA084197NCI NIH HHS R01 CA172113NIDDK NIH HHS DK052230NIDDK NIH HHS R01 DK052230NIDDK NIH HHS R01 DK093680
6 · The paper itself

Abstract

unlabelledThe zinc finger transcription factor Krüppel-like factor 4 (KLF4) is frequently downregulated in colorectal cancer. Previous studies showed that KLF4 is a tumor suppressor in the intestinal tract and plays an important role in DNA damage-repair mechanisms. Here, the in vivo effects of Klf4 deletion were examined from the mouse intestinal epithelium (Klf4(ΔIS)) in a genetic or pharmacological setting of colonic tumorigenesis:Apc(Min/⁺) mutation or carcinogen treatment with azoxymethane (AOM), respectively.Klf4 (ΔIS)/Apc (Min/⁺) mice developed significantly more colonic adenomas with 100% penetrance as compared with Apc(Min/⁺) mice with intact Klf4 (Klf4(fl/fl)/Apc (Min/⁺)). The colonic epithelium of Klf4 (ΔIS)/Apc (Min/⁺)mice showed increased mTOR pathway activity, together with dysregulated epigenetic mechanism as indicated by altered expression of HDAC1 and p300. Colonic adenomas from both genotypes stained positive for γH2AX, indicating DNA double-strand breaks. InKlf4 (ΔIS)/Apc (Min/+) mice, this was associated with reduced nonhomologous end joining (NHEJ) repair and homologous recombination repair (HRR) mechanisms as indicated by reduced Ku70 and Rad51 staining, respectively. In a separate model, following treatment with AOM, Klf4 (ΔIS) mice developed significantly more colonic tumors than Klf4 (fl/fl) mice, with more Klf4 (ΔIS) mice harboring K-Rasmutations than Klf4 (fl/fl)mice. Compared with AOM-treated Klf4 (fl/fl)mice, adenomas of treated Klf4 (ΔIS) mice had suppressed NHEJ and HRR mechanisms, as indicated by reduced Ku70 and Rad51 staining. This study highlights the important role of KLF4 in suppressing the development of colonic neoplasia under different tumor-promoting conditions. IMPLICATIONS: The study demonstrates that KLF4 plays a significant role in the pathogenesis of colorectal neoplasia.

Indexed as

MutationAdenomatous Polyposis Coli ProteinAnimalsAzoxymethaneCells, CulturedColonic NeoplasmsEpigenesis, GeneticGene DeletionGene Expression Regulation, NeoplasticHCT116 CellsHumansIntestinal MucosaKruppel-Like Factor 4Kruppel-Like Transcription FactorsMiceNeoplasms, ExperimentalAdenomatous Polyposis Coli Proteinadenomatous polyposis coli protein, mouseAzoxymethaneKLF4 protein, humanKlf4 protein, mouseKruppel-Like Factor 4Kruppel-Like Transcription FactorsmTOR protein, mouseTOR Serine-Threonine Kinases

Identifiers

PMID26839262
PMCPMC4834227
OpenAlexW2262599920

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.